Who are IMOJEV's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): JE vaccine new plant lot 2, JE Vaccine existing facility, JE vaccine new plant lot 1, C) primary immunizations with Ixiaro, JECEVAX, JE vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/imojev.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

IMOJEV — Competitive Intelligence Brief

IMOJEV (IMOJEV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated vaccine. Area: Infectious Disease / Immunology.

phase 3 Live attenuated vaccine Japanese encephalitis virus Infectious Disease / Immunology Biologic Live · refreshed every 30 min

Target snapshot

IMOJEV (IMOJEV) — SK Bioscience Co., Ltd.. IMOJEV is a live attenuated Japanese encephalitis virus vaccine that stimulates immune responses to prevent Japanese encephalitis infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
IMOJEV TARGET	IMOJEV	SK Bioscience Co., Ltd.	phase 3	Live attenuated vaccine	Japanese encephalitis virus
JE vaccine new plant lot 2	JE vaccine new plant lot 2	International Centre for Diarrhoeal Disease Research, Bangladesh	marketed	vaccine	Japanese encephalitis virus envelope proteins
JE Vaccine existing facility	JE Vaccine existing facility	International Centre for Diarrhoeal Disease Research, Bangladesh	marketed	Vaccine	Japanese encephalitis virus envelope proteins
JE vaccine new plant lot 1	JE vaccine new plant lot 1	International Centre for Diarrhoeal Disease Research, Bangladesh	marketed	vaccine	Japanese encephalitis virus envelope proteins
C) primary immunizations with Ixiaro	C) primary immunizations with Ixiaro	Helsinki University Central Hospital	phase 3	Inactivated viral vaccine	Japanese encephalitis virus envelope and non-structural proteins
JECEVAX	JECEVAX	National Institute of Hygiene and Epidemiology, Vietnam	phase 3	Live attenuated vaccine	Japanese encephalitis virus envelope proteins
JE vaccine	JE vaccine	Boryung Pharmaceutical Co., Ltd	phase 3	Vaccine	Japanese encephalitis virus envelope proteins

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated vaccine class)

GlaxoSmithKline · 19 drugs in this class
Merck Sharp & Dohme LLC · 11 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
PATH · 5 drugs in this class
Sanofi · 5 drugs in this class
Bandim Health Project · 5 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Beijing Center for Disease Control and Prevention · 2 drugs in this class
Aga Khan University · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IMOJEV — Competitive Intelligence Brief. https://druglandscape.com/ci/imojev. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab